Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$23.53 -1.3%	$22.18	$13.40 ▼ $25.23	$3.94B	0.7	1.63 million shs	1.75 million shs
AXSM Axsome Therapeutics	$103.02 +1.6%	$105.84	$72.21 ▼ $139.13	$5.07B	0.51	635,684 shs	838,764 shs
OGN Organon & Co.	$9.76 +0.6%	$9.78	$8.01 ▼ $23.10	$2.53B	0.6	3.43 million shs	3.69 million shs
PRGO Perrigo	$26.69 +0.1%	$27.01	$23.14 ▼ $30.93	$3.66B	0.47	864,587 shs	1.12 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	0.00%	+1.20%	+12.32%	+57.81%	+23.71%
AXSM Axsome Therapeutics	0.00%	+2.17%	-2.22%	-8.19%	+17.99%
OGN Organon & Co.	0.00%	-4.08%	-3.13%	+1.67%	-55.33%
PRGO Perrigo	0.00%	-6.05%	-1.87%	+4.05%	-5.56%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	3.9842 of 5 stars	3.4	3.0	0.0	0.0	2.5	4.2	2.5
AXSM Axsome Therapeutics	4.8172 of 5 stars	4.5	3.0	0.0	4.5	2.9	4.2	0.6
OGN Organon & Co.	4.8718 of 5 stars	3.3	4.0	1.7	3.7	2.7	3.3	2.5
PRGO Perrigo	4.4273 of 5 stars	2.1	2.0	4.2	3.5	2.6	1.7	2.5

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$28.13	19.53% Upside
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.28% Upside
OGN Organon & Co.	2.50	Moderate Buy	$18.00	84.43% Upside
PRGO Perrigo	2.25	Hold	$33.00	23.64% Upside

Current Analyst Ratings Breakdown

Latest OGN, PRGO, ACAD, and AXSM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/24/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$30.00 ➝ $34.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/12/2025	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$193.00 ➝ $186.00
6/10/2025	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$180.00
6/9/2025	AXSM Axsome Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$153.00 ➝ $150.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00

(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	4.11	$0.70 per share	33.38	$4.40 per share	5.35
AXSM Axsome Therapeutics	$385.69M	13.15	N/A	N/A	$1.18 per share	87.31
OGN Organon & Co.	$6.40B	0.40	$4.93 per share	1.98	$1.83 per share	5.33
PRGO Perrigo	$4.37B	0.84	$5.05 per share	5.28	$31.66 per share	0.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	17.18	30.96	6.54	22.97%	17.46%	10.75%	8/6/2025 (Estimated)
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.53	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
OGN Organon & Co.	$864M	$2.88	3.39	2.61	1.01	11.92%	227.43%	7.34%	8/5/2025 (Estimated)
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.72	N/A	-4.16%	8.93%	3.87%	8/6/2025 (Estimated)

Latest OGN, PRGO, ACAD, and AXSM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	ACAD ACADIA Pharmaceuticals	$0.14	N/A	N/A	N/A	$263.07 million	N/A
8/6/2025	Q2 2025	PRGO Perrigo	$0.59	N/A	N/A	N/A	$1.08 billion	N/A
8/5/2025	Q2 2025	OGN Organon & Co.	$0.93	N/A	N/A	N/A	$1.55 billion	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
OGN Organon & Co.	$0.08	0.82%	N/A	2.78%	N/A
PRGO Perrigo	$1.16	4.35%	N/A	N/A	23 Years

Latest OGN, PRGO, ACAD, and AXSM Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/30/2025	PRGO Perrigo	quarterly	$0.29	4.21%	8/29/2025	8/29/2025	9/16/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
AXSM Axsome Therapeutics	3.48	2.03	1.96
OGN Organon & Co.	16.49	1.67	1.15
PRGO Perrigo	0.82	2.36	1.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
AXSM Axsome Therapeutics	81.49%
OGN Organon & Co.	77.43%
PRGO Perrigo	95.91%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.50%
AXSM Axsome Therapeutics	22.30%
OGN Organon & Co.	1.96%
PRGO Perrigo	0.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	123.01 million	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
OGN Organon & Co.	4,000	259.96 million	254.86 million	Not Optionable
PRGO Perrigo	8,379	137.48 million	136.52 million	Optionable

OGN, PRGO, ACAD, and AXSM Headlines

Recent News About These Companies

XTX Topco Ltd Buys Shares of 50,341 Perrigo Company plc (NYSE:PRGO)

August 2 at 7:05 AM | marketbeat.com

Perrigo (PRGO) Expects Enhanced Profitability and Earnings Growth from Strategic Execution

August 1 at 10:15 AM | finance.yahoo.com

Perrigo Company plc (NYSE:PRGO) Announces $0.29 Quarterly Dividend

July 31 at 4:29 PM | marketbeat.com

Monaco Asset Management SAM Raises Position in Perrigo Company plc (NYSE:PRGO)

July 31 at 7:52 AM | marketbeat.com

Perrigo Announces Quarterly Dividend

July 30, 2025 | prnewswire.com

Perrigo to Report Q2 Earnings: What's in Store for the Stock?

July 30, 2025 | zacks.com

Perrigo to Present at the Canaccord Genuity 45th Annual Growth Conference

July 29, 2025 | prnewswire.com

University of Texas Texas AM Investment Management Co. Has $516,000 Stock Position in Perrigo Company plc (NYSE:PRGO)

July 28, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Cut to "Hold" at Wall Street Zen

July 28, 2025 | americanbankingnews.com

Heartland Advisors Inc. Decreases Stock Holdings in Perrigo Company plc (NYSE:PRGO)

July 26, 2025 | marketbeat.com

Perrigo (NYSE:PRGO) Lowered to Hold Rating by Wall Street Zen

July 26, 2025 | marketbeat.com

Sound Shore Management Inc. CT Raises Position in Perrigo Company plc (NYSE:PRGO)

July 25, 2025 | marketbeat.com

Is Perrigo (PRGO) Stock Undervalued Right Now?

July 25, 2025 | zacks.com

Legato Capital Management LLC Has $930,000 Stake in Perrigo Company plc (NYSE:PRGO)

July 25, 2025 | marketbeat.com

Perrigo (PRGO) to Release Quarterly Earnings on Friday

July 25, 2025 | marketbeat.com

Diamond Hill Capital Management Inc. Purchases 11,256 Shares of Perrigo Company plc (NYSE:PRGO)

July 24, 2025 | marketbeat.com

Perrigo to Release Second Quarter 2025 Financial Results on August 6, 2025

July 23, 2025 | prnewswire.com

Perrigo Company: Simpler, Cleaner, And Perhaps More Compelling

July 21, 2025 | seekingalpha.com

Victory Capital Management Inc. Grows Position in Perrigo Company plc (NYSE:PRGO)

July 20, 2025 | marketbeat.com

Edgestream Partners L.P. Reduces Stake in Perrigo Company plc (NYSE:PRGO)

July 20, 2025 | marketbeat.com

Envestnet Asset Management Inc. Purchases 102,375 Shares of Perrigo Company plc (NYSE:PRGO)

July 19, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

OGN, PRGO, ACAD, and AXSM Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$23.53 -0.30 (-1.26%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$23.17 -0.36 (-1.53%)

As of 08/1/2025 07:12 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Axsome Therapeutics NASDAQ:AXSM

$103.02 +1.64 (+1.62%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$104.02 +1.01 (+0.98%)

As of 08/1/2025 07:59 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Organon & Co. NYSE:OGN

$9.76 +0.06 (+0.62%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$9.64 -0.12 (-1.18%)

As of 08/1/2025 06:32 PM Eastern

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Perrigo NYSE:PRGO

$26.69 +0.02 (+0.07%)

Closing price 08/1/2025 03:59 PM Eastern

Extended Trading

$26.64 -0.05 (-0.17%)

As of 08/1/2025 04:20 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time